Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Hohenstein

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Kidney International|March 17, 2006
Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in manB Hohenstein, B Hausknecht, K Boehmer, et al.
Atherosclerosis. Supplements|November 4, 2017
Dysregulation of the CD4<sup>+</sup> T cells lineage differentiation in dyslipidemic patients and impact of lipoprotein-apheresis treatment: A case studyJ Papin, A Brennand, G Arbore, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 26, 2007
Transvenous renal biopsy of a kidney transplant in a patient with a suspected bleeding disorderB Hohenstein, M Uder, C Willam, et al.
Atherosclerosis. Supplements|November 4, 2017
Comparing the efficacy of three techniques to reduce isoagglutinin titers in AB0 incompatible kidney transplant recipientsS P Parmentier, E Rosenkranz, H Schirutschke, et al.
Journal of Clinical Lipidology|June 21, 2018
Treatment-related and health-related quality of life in lipoprotein apheresis patientsV De Gucht, K Cromm, A Vogt, et al.
Atherosclerosis. Supplements|November 4, 2017
Lipoprotein apheresis influences monocyte subpopulationsS Jellinghaus, C Reich, U Schatz, et al.
Clinical Research in Cardiology Supplements|March 7, 2019
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levelsV J J Schettler, C L Neumann, C Peter, et al.
Clinical and Experimental Immunology|October 27, 2016
Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disordersC Wehling, O Amon, M Bommer, et al.
Atherosclerosis|September 29, 2024
The German Lipoprotein Apheresis Registry-Summary of the eleventh annual reportV J J Schettler, N Selke, S Jenke, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Kidney International|March 17, 2006
Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in manB Hohenstein, B Hausknecht, K Boehmer, et al.
Atherosclerosis. Supplements|November 4, 2017
Dysregulation of the CD4<sup>+</sup> T cells lineage differentiation in dyslipidemic patients and impact of lipoprotein-apheresis treatment: A case studyJ Papin, A Brennand, G Arbore, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|May 26, 2007
Transvenous renal biopsy of a kidney transplant in a patient with a suspected bleeding disorderB Hohenstein, M Uder, C Willam, et al.
Atherosclerosis. Supplements|November 4, 2017
Comparing the efficacy of three techniques to reduce isoagglutinin titers in AB0 incompatible kidney transplant recipientsS P Parmentier, E Rosenkranz, H Schirutschke, et al.
Journal of Clinical Lipidology|June 21, 2018
Treatment-related and health-related quality of life in lipoprotein apheresis patientsV De Gucht, K Cromm, A Vogt, et al.
Atherosclerosis. Supplements|November 4, 2017
Lipoprotein apheresis influences monocyte subpopulationsS Jellinghaus, C Reich, U Schatz, et al.
Clinical Research in Cardiology Supplements|March 7, 2019
Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levelsV J J Schettler, C L Neumann, C Peter, et al.
Clinical and Experimental Immunology|October 27, 2016
Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disordersC Wehling, O Amon, M Bommer, et al.
Atherosclerosis|September 29, 2024
The German Lipoprotein Apheresis Registry-Summary of the eleventh annual reportV J J Schettler, N Selke, S Jenke, et al.
Pageof 2